Talus Bio

Discovering drugs that target the DNA regulome

Y CombinatorSummer 2021ActiveHealthcareDrug Discovery and DeliveryBiotechGenomicsDrug discovery

What they do

Problem

Many genome-regulating proteins are effectively undruggable because traditional drug discovery assays in artificial systems don’t capture their true function in human cells.

Solution

A live-human-cell drug discovery platform using automated cell processing, next-gen proteomics, and data analytics to measure a drug’s impact across the entire DNA regulome in one experiment.

Who it's for

Pharmaceutical companies and biotech researchers developing therapies that target genome regulators.

Founders

Alex Federation

Founder

I'm the co-founder of Talus Bio. Prior to Talus, I trained with Jay Bradner at Harvard in medicinal chemistry, drug screening, and drug development for gene regulators. After that, I moved to Seattle to continue my training in epigenomics and proteomics, and these were all combined to develop the Talus gene regulator platform.

LinkedIn · X

Lindsay Pino

Founder

I'm Talus Bio's CTO, where my focus is on developing techniques for quantitative proteomics and in particular the challenges associated with scaling-up quantitative proteomics experiments. I’ve trained at the Broad Institute, the University of Washington, and most recently the University of Pennsylvania.

LinkedIn · X